3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide has been researched along with ADDH in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abi-Dargham, A; Gelernter, J; Innis, RB; Kegeles, L; Laruelle, M; Martinez, D; van Dyck, CH | 1 |
1 other study(ies) available for 3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide and ADDH
| Article | Year |
|---|---|
The variable number of tandem repeats polymorphism of the dopamine transporter gene is not associated with significant change in dopamine transporter phenotype in humans.
Topics: Adult; Amphetamine; Attention Deficit Disorder with Hyperactivity; Benzamides; Carrier Proteins; Cocaine; Cocaine-Related Disorders; Dopamine; Dopamine Antagonists; Dopamine Plasma Membrane Transport Proteins; Genotype; Humans; Iodine Radioisotopes; Membrane Glycoproteins; Membrane Transport Proteins; Minisatellite Repeats; Neostriatum; Nerve Tissue Proteins; Phenotype; Polymorphism, Genetic; Psychotic Disorders; Pyrrolidines; Radiopharmaceuticals; Schizophrenia; Tomography, Emission-Computed, Single-Photon | 2001 |